与路易体痴呆:病理基础的扣带岛标志(P6.332)

文摘

摘要目的:探讨临床、影像和病理协会的扣带岛(CIS)和路易体痴呆迹象(下文)。背景:下文的临床诊断仍然不佳,尽管改善临床标准。抽出后扣带相对于楔片和楔前叶(CIS),已被建议作为[18 f] 2-fluoro-deoxy-D-glucose (FDG) PET生物标记区分下文与阿尔茨海默病(AD),但这个标志的病理基础是不清楚。设计/方法:我们回顾性确定连续病例的临床诊断下文(n = 39)和匹配广告(n = 39)和患者认知正常受试者(n = 78)接受FDG和11 c-pittsburgh化合物b(加以)PET扫描。我们研究的病人尸检(n = 10)和接受Braak-neurofibrillary混乱(非功能性测试)阶段。结果:受试者的临床诊断下文亦有明显高于CIS FDG PET相比,广告主题(p < 0.001),这是独立存在的β-amyloid负载加以宠物(p = 0.66)。尸检确诊病例,6/8的患者临床诊断下文的中间或高可能性下文病理学和积极的CIS FDG PET的视觉评估。2/8与临床下文但负面CIS AD病理诊断。CIS是消极的广告在两个患者临床诊断,证实了尸检。更高的CIS与较低的Braak-NFT阶段(r = -0.92;p < 0.001)。结论:我们的研究发现,独联体的存在FDG PET与β-amyloid负载无关,但表明较低的Braak-NFT阶段患者的下文。积极的CIS患者适合高或中间概率下文病理组和临床诊断为下文不是广告。生物学标志物,可以测量的相对贡献基础疾病患者的痴呆是至关重要的,神经病治疗走向有针对性的治疗。研究支持:AG040042 / AG11378 AG16574 / AG06786 Mangurian基础

披露:Graff-Radford博士没有披露。莫瑞没有披露。劳博士已经收到个人补偿活动劳博士与拜耳制药公司已经收到了来自通用电气医疗研究支持,西门子分子成像,AVID Radiopharmaceuticals, Inc . Boeve博士已经收到头研究支持,Inc . Allon疗法,通用电气医疗集团。Ferman博士没有披露。Przybelski博士没有披露。Lesnick博士已经收到个人赔偿的活动与生殖医学和不孕的同事作为顾问。Senjem博士没有披露。甘特博士没有披露。史密斯博士没有披露。Knopman博士已经收到个人赔偿的活动与礼来公司和TauRx药品。 Dr. Knopman has received personal compensation in an editorial capacity for Neurology. Dr. Knopman has received research support from Janssen and Baxter. Dr. Jack has received personal compensation for activities with Janssen, Eisai Inc., General Electric, Johnson & Johnson, and Eli Lilly & Co. Dr. Jack has received research support from Pfizer Inc., Allon, and Baxter. Dr. Dickson has received personal compensation for activities with Neotope, Inc. as a consultant. Dr. Petersen has received personal compensation for activities with Pfizer, Inc., and Janssen Alzheimer's Immunotherapy. Dr. Petersen has received royalty payments from Oxford University Press. Dr. Kantarci has received research support from Pfizer Inc., Jannsen Alzheimer immunotherapy, and Takeda Global Research & Development Center.